Sodium Butyrate Selectively Kills Cancer Cells and Inhibits Migration in Colorectal Cancer by Targeting Thioredoxin-1

Wenqi Wang1,2, Daoquan Fang3, Hao Zhang1

  • 1Department of Microbiology and Immunology, School of Laboratory Medicine, Wenzhou Medical University, Wenzhou 325000, People's Republic of China.

Abstract

Insights

Sodium butyrate (NaB) inhibits colorectal cancer (CRC) growth by decreasing thioredoxin-1 (Trx-1) expression. Downregulating Trx-1 enhances NaB's anti-tumor effects, indicating Trx-1's crucial role in NaB's efficacy against CRC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Sodium butyrate (NaB), a short-chain fatty acid from dietary fiber fermentation, exhibits anti-tumor properties in various cancers, including colorectal cancer (CRC).
  • The precise mechanism by which NaB exerts its anti-tumor effects, particularly the involvement of thioredoxin-1 (Trx-1), remains incompletely understood in CRC.

Purpose of the Study:

  • To investigate the role of thioredoxin-1 (Trx-1) in the anti-tumor effects of sodium butyrate (NaB) on colorectal cancer (CRC) cells.
  • To elucidate the molecular mechanisms underlying NaB-induced growth inhibition, apoptosis, and migration in CRC.

Main Methods:

  • Cell Counting Kit-8 and colony formation assays were used to assess cell viability and proliferation.
  • Flow cytometry and Transwell assays evaluated apoptosis and cell migration, respectively.
  • Western blotting, reactive oxygen species (ROS) measurement, and in vivo xenograft models were employed to analyze Trx-1 expression, ROS levels, and tumor growth.

Main Results:

  • NaB significantly inhibited CRC cell growth, induced apoptosis, and suppressed migration and epithelial-to-mesenchymal transition (EMT).
  • NaB treatment led to decreased Trx-1 protein expression and increased ROS levels in CRC cells.
  • Downregulation of Trx-1 potentiated NaB's anti-tumor effects, while Trx-1 overexpression attenuated them.

Conclusions:

  • The anti-tumor effects of NaB in colorectal cancer are significantly associated with the downregulation of thioredoxin-1 (Trx-1).
  • Targeting Trx-1 may represent a promising strategy to enhance the efficacy of NaB as an anti-cancer therapeutic for CRC.